Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 468-478

  Guerrero Muñoz, Marcos J ^a,b   Castillo Carranza, Diana L ^a,b   Kayed, Rakez ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Amyloid oligomers; Anti amyloid small molecules; Immunotherapy

Indexed keywords

ALPHA SYNUCLEIN; AMYLIN; AMYLOID PROTEIN; BAICALEIN; CURCUMIN; EPIGALLOCATECHINGALLATE; INSULIN; LYSOZYME; METHYLENE BLUE; OLEUROPEIN; OLIGOMER; POLYGLUTAMINE; PRION PROTEIN; PROTEIN P53; RESVERATROL; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; MOLECULE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; REVIEW; THERAPY EFFECT;

ANLE138B (HTTP://WWW.CIPSM.DE/EN/PUBLICATIONS/RESEARCHAREAA/2013/ANLE138B_A_NOVEL_OLIGOMER_MODULATOR_FOR_DISEASE-MODIFYING_THERAPY_OF_NEURODEGENERATIVE_DISEASES_SUCH_AS_PRION_AND_PARKINSON_S_DISEASE/INDEX.HTML?STYLE=1); AMYLOID OLIGOMERS; ANTI-AMYLOID SMALL MOLECULES; BAICALEIN (PUBCHEM CID: 5281605); CLR01 (HTTP://WWW.MED-CHEMIST.COM/2012/11/CLR01-EFFECTIVELY-INHIBITS.HTML); CURCUMIN (PUBCHEM CID: 969516); EPIGALLOCATECHINGALLATE (PUBCHEM CID: 65064); IMMUNOTHERAPY; METHYLENE BLUE (PUBCHEM CID: 6099); OLEUROPEIN (PUBCHEM CID: 5281544); PHENOL RED (PUBCHEM CID: 4766); RESVERATROL (PUBCHEM CID: 445154); SILIBININ (PUBCHEM CID: 31553);

AMYLOIDOGENIC PROTEINS; ANIMALS; BIOPOLYMERS; IMMUNOTHERAPY; MICE;

EID: 84897954120     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.12.023     Document Type: Review

References (221)

1. R.D. Terry The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis J Neuropathol Exp Neurol 55 1996 1023 1025 (Pubitemid 26338013)
2. A. Lorenzo, and B.A. Yankner Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red PNAS 91 1994 12243 12247 (Pubitemid 24368641)
3. C.J. Pike, D. Burdick, A.J. Walencewicz, C.G. Glabe, and C.W. Cotman Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state J Neurosci 13 1993 1676 1687 (Pubitemid 23095409)
4. C.J. Pike, A.J. Walencewicz, C.G. Glabe, and C.W. Cotman In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity Brain Res 563 1991 311 314
5. T. Okada, M. Wakabayashi, K. Ikeda, and K. Matsuzaki Formation of toxic fibrils of Alzheimer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component J Mol Biol 371 2007 481 489 (Pubitemid 47048280)
6. V. Novitskaya, O.V. Bocharova, I. Bronstein, and I.V. Baskakov Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons J Biol Chem 281 2006 13828 13836 (Pubitemid 43855298)
7. R. Katzman, R. Terry, R. DeTeresa, T. Brown, P. Davies, and P. Fuld et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques Ann Neurol 23 1988 138 144 (Pubitemid 18081451)
8. S. Baglioni, F. Casamenti, M. Bucciantini, L.M. Luheshi, N. Taddei, and F. Chiti et al. Prefibrillar amyloid aggregates could be generic toxins in higher organisms J Neurosci 26 2006 8160 8167 (Pubitemid 44315140)
9. C. Haass, and D.J. Selkoe Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide Nat Rev Mol Cell Biol 8 2007 101 112 (Pubitemid 46432529)
10. J. Hardy The amyloid hypothesis for Alzheimer's disease: a critical reappraisal J Neurochem 110 2009 1129 1134
11. R. Cappai, and K.J. Barnham Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity Neurochem Res 33 2008 526 532 (Pubitemid 351230455)
12. C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, and K. Beyreuther et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann Neurol 46 1999 860 866
13. L.F. Lue, Y.M. Kuo, A.E. Roher, L. Brachova, Y. Shen, and L. Sue et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease Am J Pathol 155 1999 853 862 (Pubitemid 29426831)
14. J.L. Tomic, A. Pensalfini, E. Head, and C.G. Glabe Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction Neurobiol Dis 35 2009 352 358
15. M. Hoshi, M. Sato, S. Matsumoto, A. Noguchi, K. Yasutake, and N. Yoshida et al. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta PNAS 100 2003 6370 6375 (Pubitemid 36666588)
16. S. Barghorn, V. Nimmrich, A. Striebinger, C. Krantz, P. Keller, and B. Janson et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease J Neurochem 95 2005 834 847 (Pubitemid 41567174)
17. G. Habicht, C. Haupt, R.P. Friedrich, P. Hortschansky, C. Sachse, and J. Meinhardt et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils PNAS 104 2007 19232 19237
18. A. Eckert, S. Hauptmann, I. Scherping, J. Meinhardt, V. Rhein, and S. Drose et al. Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice J Mol Med (Berl) 86 2008 1255 1267
19. M. Fandrich Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity J Mol Biol 421 2012 427 440
20. J.D. Harper, S.S. Wong, C.M. Lieber, and P.T. Lansbury Observation of metastable A beta amyloid protofibrils by atomic force microscopy Chem Biol 4 1997 119 125 (Pubitemid 27161750)
21. C.S. Goldsbury, S. Wirtz, S.A. Muller, S. Sunderji, P. Wicki, and U. Aebi et al. Studies on the in vitro assembly of a beta 1-40: implications for the search for a beta fibril formation inhibitors J Struct Biol 130 2000 217 231
22. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, and C.W. Cotman et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489 (Pubitemid 36444329)
23. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, and M. Liosatos et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins PNAS 95 1998 6448 6453
24. A.Y. Hsia, E. Masliah, L. McConlogue, G.Q. Yu, G. Tatsuno, and K. Hu et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models PNAS 96 1999 3228 3233 (Pubitemid 29148873)
25. L. Mucke, E. Masliah, G.Q. Yu, M. Mallory, E.M. Rockenstein, and G. Tatsuno et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation J Neurosci 20 2000 4050 4058 (Pubitemid 30365675)
26. R. Kayed, I. Canto, L. Breydo, S. Rasool, T. Lukacsovich, and J. Wu et al. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers Mol Neurodegener 5 2010 57
27. R. Kayed, E. Head, F. Sarsoza, T. Saing, C.W. Cotman, and M. Necula et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers Mol Neurodegener 2 2007 18
28. M.J. Guerrero-Munoz, D.L. Castillo-Carranza, U. Sengupta, M.A. White, and R. Kayed Design of metastable beta-sheet oligomers from natively unstructured peptide ACS Chem Neurosci 4 2013 1520 1523
29. A. Sanbe, T. Marunouchi, T. Abe, Y. Tezuka, M. Okada, and S. Aoki et al. Phenotype of cardiomyopathy in cardiac-specific heat shock protein B8 K141N transgenic mouse J Biol Chem 288 2013 8910 8921
30. M.L. Evans, J.C. Schmidt, M. Ilbert, S.M. Doyle, S. Quan, and J.C. Bardwell et al. E. coli chaperones DnaK, Hsp33 and Spy inhibit bacterial functional amyloid assembly Prion 5 2011 323 334
31. C.A. Lasagna-Reeves, A.L. Clos, D. Castillo-Carranza, U. Sengupta, M. Guerrero-Munoz, and B. Kelly et al. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity Biochem Biophys Res Commun 430 2013 963 968
32. F.H. Aidt, L.F. Hasholt, M. Christiansen, and H. Laursen Localization of A11-reactive oligomeric species in prion diseases Histopathology 62 2013 994 1001
33. T.M. Shin, J.M. Isas, C.L. Hsieh, R. Kayed, C.G. Glabe, and R. Langen et al. Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin Mol Neurodegener 3 2008 16
34. E. Andreetto, L.M. Yan, M. Tatarek-Nossol, A. Velkova, R. Frank, and A. Kapurniotu Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross- and self-association Angew Chem Int Ed Engl 49 2010 3081 3085
35. S.M. Butterfield, and H.A. Lashuel Amyloidogenic protein-membrane interactions: mechanistic insight from model systems Angew Chem Int Ed Engl 49 2010 5628 5654
36. M. Guerrero-Munoz, D. Castillo-Carranza, C. Lasagna-Reeves, U. Sengupta, S. Krishnamurthy, and G. Jackson et al. Formation of toxic oligomeric species from different proteins in Alzheimer's disease: potential toxic interactions at the oligomer aggregation stage Alzheimers Dement 9 2013 P305
37. R. Kayed, A. Pensalfini, L. Margol, Y. Sokolov, F. Sarsoza, and E. Head et al. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer J Biol Chem 284 2009 4230 4237
38. J.W. Wu, L. Breydo, J.M. Isas, J. Lee, Y.G. Kuznetsov, and R. Langen et al. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid {beta} but do not seed fibril formation J Biol Chem 285 2010 6071 6079
39. R. Kayed, Y. Sokolov, B. Edmonds, T.M. McIntire, S.C. Milton, and J.E. Hall et al. Permeabilization of lipid bilayers is a common conformation- dependent activity of soluble amyloid oligomers in protein misfolding diseases J Biol Chem 279 2004 46363 46366 (Pubitemid 39518276)
40. D.M. Walsh, D.M. Hartley, Y. Kusumoto, Y. Fezoui, M.M. Condron, and A. Lomakin et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates J Biol Chem 274 1999 25945 25952
41. K.A. Conway, J.D. Harper, and P.T. Lansbury Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid Biochemistry 39 2000 2552 2563 (Pubitemid 30148907)
42. C. Ionescu-Zanetti, R. Khurana, J.R. Gillespie, J.S. Petrick, L.C. Trabachino, and L.J. Minert et al. Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy PNAS 96 1999 13175 13179
43. A. Quintas, D.C. Vaz, I. Cardoso, M.J.M. Saraiva, and R.M.M. Brito Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants J Biol Chem 276 2001 27207 27213
44. W.S. Gosal, I.J. Morten, E.W. Hewitt, D.A. Smith, N.H. Thomson, and S.E. Radford Competing pathways determine fibril morphology in the self-assembly of beta(2)-microglobulin into amyloid J Mol Biol 351 2005 850 864 (Pubitemid 41111901)
45. M. Malisauskas, V. Zamotin, J. Jass, W. Noppe, C.M. Dobson, and L.A. Morozova-Roche Amyloid protofilaments from the calcium-binding protein equine lysozyme: formation of ring and linear structures depends on pH and metal ion concentration J Mol Biol 330 2003 879 890
46. G. Plakoutsi, N. Taddei, M. Stefani, and F. Chiti Aggregation of the acylphosphatase from Sulfolobus solfataricus - the folded and partially unfolded states can both be precursors for amyloid formation J Biol Chem 279 2004 14111 14119 (Pubitemid 38468947)
47. R. Bader, R. Bamford, J. Zurdo, B.F. Luisi, and C.M. Dobson Probing the mechanism of amyloidogenesis through a tandem repeat of the PI3-SH3 domain suggests a generic model for protein aggregation and fibril formation J Mol Biol 356 2006 189 208 (Pubitemid 43069737)
48. F. Saudou, S. Finkbeiner, D. Devys, and M.E. Greenberg Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions Cell 95 1998 55 66
49. M.M. Tompkins, and W.D. Hill Contribution of somal Lewy bodies to neuronal death Brain Res 775 1997 24 29 (Pubitemid 28020485)
50. M. Arrasate, S. Mitra, E.S. Schweitzer, M.R. Segal, and S. Finkbeiner Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death Nature 431 2004 805 810 (Pubitemid 39434070)
51. E.J. Bennett, T.A. Shaler, B. Woodman, K.Y. Ryu, T.S. Zaitseva, and C.H. Becker et al. Global changes to the ubiquitin system in Huntington's disease Nature 448 2007 704 708 (Pubitemid 47236860)
52. R.G.M. Morris, P. Garrud, J.N.P. Rawlins, and J. O'Keefe Place navigation impaired in rats with hippocampal lesions Nature 297 1982 681 683 (Pubitemid 12096189)
53. F. Yamaguchi Transgenic mice for the amyloid precursor protein 695 isoform have impaired spatial memory NeuroReport 2 1991 781 784
54. R. D'Hooge, G. Nagels, C.E. Westland, L. Muck, and P.P. De Deyn Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein NeuroReport 7 1996 2807 2811 (Pubitemid 26403065)
55. J. Nalbantoglu Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein Nature 387 1997 500 505 (Pubitemid 27235467)
56. A. Justice, and R. Motter Behavioral characterization of PDAPP transgenic Alzheimer mice Soc Neurosci Abstr 23 1997 1637
57. D. Moechars Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain J Biol Chem 274 1999 6483 6492 (Pubitemid 29111064)
58. J. Raber Apolipoprotein E and cognitive performance Nature 404 2000 352 354 (Pubitemid 30164327)
59. M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, and J. Zurdo et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases Nature 416 2002 507 511 (Pubitemid 34288846)
60. R.M. Koffie, M. Meyer-Luehmann, T. Hashimoto, K.W. Adams, M.L. Mielke, and M. Garcia-Alloza et al. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques PNAS 106 2009 4012 4017
61. I.C. Martins, I. Kuperstein, H. Wilkinson, E. Maes, M. Vanbrabant, and W. Jonckheere et al. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice EMBO J 27 2008 224 233
62. C. Zussy, A. Brureau, E. Keller, S. Marchal, C. Blayo, and B. Delair et al. Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-beta peptide injection in rats PLoS One 8 2013 e53117
63. B. Mazur-Kolecka, A. Golabek, K. Nowicki, M. Flory, and J. Frackowiak Amyloid-beta impairs development of neuronal progenitor cells by oxidative mechanisms Neurobiol Aging 27 2006 1181 1192 (Pubitemid 44067306)
64. D.F. Silva, A.R. Esteves, D.M. Arduino, C.R. Oliveira, and S.M. Cardoso Amyloid-beta-induced mitochondrial dysfunction impairs the autophagic lysosomal pathway in a tubulin dependent pathway J Alzheimers Dis 26 2011 565 581
65. C.A. Lasagna-Reeves, D.L. Castillo-Carranza, U. Sengupta, A.L. Clos, G.R. Jackson, and R. Kayed Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice Mol Neurodegener 6 2011 39
66. P.F. Teixeira, F. Cerca, S.D. Santos, and M.J. Saraiva Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy J Biol Chem 281 2006 21998 22003 (Pubitemid 44181903)
67. K. Heinitz, M. Beck, R. Schliebs, and J.R. Perez-Polo Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergic SN56.B5.G4 cells J. Neurochem 98 2006 1930 1945 (Pubitemid 44298256)
68. S. Casas, R. Gomis, F.M. Gribble, J. Altirriba, S. Knuutila, and A. Novials Impairment of the ubiquitin-proteasome pathway is a downstream endoplasmic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic beta-cell apoptosis Diabetes 56 2007 2284 2294 (Pubitemid 47358235)
69. K. Nishitsuji, T. Tomiyama, K. Ishibashi, K. Ito, R. Teraoka, and M.P. Lambert et al. The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells Am J Pathol 174 2009 957 969
70. A.V. Matveyenko, T. Gurlo, M. Daval, A.E. Butler, and P.C. Butler Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress Diabetes 58 2009 906 916
71. S. Ito, K. Nakaso, K. Imamura, T. Takeshima, and K. Nakashima Endogenous catecholamine enhances the dysfunction of unfolded protein response and alpha-synuclein oligomerization in PC12 cells overexpressing human alpha-synuclein Neurosci Res 66 2009 124 130
72. B.J. Tabner, S. Turnbull, O. El-Agnaf, and D. Allsop Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases Curr Top Med Chem 1 2001 507 517
73. X. Huang, C.S. Atwood, M.A. Hartshorn, G. Multhaup, L.E. Goldstein, and R.C. Scarpa et al. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction Biochemistry 38 1999 7609 7616 (Pubitemid 29289332)
74. S. Turnbull, B.J. Tabner, O.M. El-Agnaf, S. Moore, Y. Davies, and D. Allsop alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro Free Radical Biol Med 30 2001 1163 1170 (Pubitemid 32441842)
75. S. Turnbull, B.J. Tabner, D.R. Brown, and D. Allsop Copper-dependent generation of hydrogen peroxide from the toxic prion protein fragment PrP 106-126 Neurosci Lett 336 2003 159 162 (Pubitemid 36044603)
76. H. Shoval, L. Weiner, E. Gazit, M. Levy, I. Pinchuk, and D. Lichtenberg Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS Biochim Biophys Acta 1784 2008 1570 1577
77. M.P. Mattson, and Y. Goodman Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium Brain Res 676 1995 219 224
78. L. Zheng, J. Calvo-Garrido, M. Hallbeck, K. Hultenby, J. Marcusson, and A. Cedazo-Minguez et al. Intracellular localization of amyloid-beta peptide in SH-SY5Y neuroblastoma cells J Alzheimers Dis 37 2013 713 733
79. J. Leitman, F. Ulrich Hartl, and G.Z. Lederkremer Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress Nat Commun 4 2013 2753
80. D. Bergemalm, K. Forsberg, V. Srivastava, K.S. Graffmo, P.M. Andersen, and T. Brannstrom et al. Superoxide dismutase-1 and other proteins in inclusions from transgenic amyotrophic lateral sclerosis model mice J Neurochem 114 2010 408 418
81. C. Terracciano, A. Nogalska, W.K. Engel, and V. Askanas In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis J Neurochem 112 2009 389 396
82. S.D. Ryan, S.N. Whitehead, L.A. Swayne, T.C. Moffat, W. Hou, and M. Ethier et al. Amyloid-beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism PNAS 106 2009 20936 20941
83. R. Resende, E. Ferreiro, C. Pereira, and C.R. Oliveira ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation J Neurosci Res 86 2008 2091 2099
84. D.L. Castillo-Carranza, Y. Zhang, M.J. Guerrero-Munoz, R. Kayed, D.E. Rincon-Limas, and P. Fernandez-Funez Differential activation of the ER stress factor XBP1 by oligomeric assemblies Neurochem Res 37 2012 1707 1717
85. U. Keil, S. Hauptmann, A. Bonert, I. Scherping, A. Eckert, and W.E. Muller Mitochondrial dysfunction induced by disease relevant AbetaPP and tau protein mutations J Alzheimers Dis 9 2006 139 146 (Pubitemid 44078641)
86. A. Wilkaniec, J.B. Strosznajder, and A. Adamczyk Toxicity of extracellular secreted alpha-synuclein: its role in nitrosative stress and neurodegeneration Neurochem Int 62 2013 776 783
87. T. Umeda, T. Tomiyama, N. Sakama, S. Tanaka, M.P. Lambert, and W.L. Klein et al. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo J Neurosci Res 89 2011 1031 1042
88. T. Gurlo, S. Ryazantsev, C.J. Huang, M.W. Yeh, H.A. Reber, and O.J. Hines et al. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway Am J Pathol 176 2010 861 869
89. J.F. Rivera, T. Gurlo, M. Daval, C.J. Huang, A.V. Matveyenko, and P.C. Butler et al. Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic beta-cells: protective role of p62-positive cytoplasmic inclusions Cell Death Differ 18 2010 415 426
90. R.C. Gaspar, S.A. Villarreal, N. Bowles, R.W. Hepler, J.G. Joyce, and P.J. Shughrue Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model Exp Neurol 223 2010 394 400
91. R.H. Takahashi, C.G. Almeida, P.F. Kearney, F. Yu, M.T. Lin, and T.A. Milner et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain J Neurosci 24 2004 3592 3599 (Pubitemid 38481116)
92. H.J. Lee, J.E. Suk, E.J. Bae, J.H. Lee, S.R. Paik, and S.J. Lee Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein Int J Biochem Cell Biol 40 2008 1835 1849
93. S. Narayanan, B. Bosl, S. Walter, and B. Reif Importance of low-oligomeric-weight species for prion propagation in the yeast prion system Sup35/Hsp104 PNAS 100 2003 9286 9291 (Pubitemid 37033921)
94. C. Yu, E. Nwabuisi-Heath, K. Laxton, and M.J. LaDu Endocytic pathways mediating oligomeric Abeta42 neurotoxicity Mol Neurodegener 5 2010 1 11
95. B. Frost, R.L. Jacks, and M.I. Diamond Propagation of Tau misfolding from the outside to the inside of a cell J Biol Chem 284 2009 12845 12852
96. E. Ahmad, A. Ahmad, S. Singh, M. Arshad, A.H. Khan, and R.H. Khan A mechanistic approach for islet amyloid polypeptide aggregation to develop anti-amyloidogenic agents for type-2 diabetes Biochimie 93 2011 793 805
97. Y. Hirakura, R. Azimov, R. Azimova, and B.L. Kagan Polyglutamine-induced ion channels: a possible mechanism for the neurotoxicity of Huntington and other CAG repeat diseases J Neurosci Res 60 2000 490 494 (Pubitemid 30252911)
98. 2+ channels provides a mechanism for neuronal death in Alzheimer's disease Ann NY Acad Sci 747 1994 256 266
99. N. Arispe, E. Rojas, and H.B. Pollard Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum PNAS 90 1993 567 571 (Pubitemid 23028904)
100. H.A. Lashuel, D. Hartley, B.M. Petre, T. Walz, and P.T. Lansbury Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations Nature 418 2002 291 (Pubitemid 34790672)
101. T. Mirzabekov, M.C. Lin, W.L. Yuan, P.J. Marshall, M. Carman, and K. Tomaselli et al. Channel formation in planar lipid bilayers by a neurotoxic fragment of the beta-amyloid peptide Biochem Biophys Res Commun 202 1994 1142 1148
102. T.A. Mirzabekov, M.C. Lin, and B.L. Kagan Pore formation by the cytotoxic islet amyloid peptide amylin J Biol Chem 271 1996 1988 1992 (Pubitemid 26047780)
103. B. Bechinger Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin J Membr Biol 156 1997 197 211 (Pubitemid 27208423)
104. S.M. Yatin, M. Aksenova, M. Aksenov, W.R. Markesbery, T. Aulick, and D.A. Butterfield Temporal relations among amyloid beta-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses J Mol Neurosci 11 1998 183 197 (Pubitemid 29232849)
105. A. Demuro, E. Mina, R. Kayed, S.C. Milton, I. Parker, and C.G. Glabe Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers J Biol Chem 280 2005 17294 17300 (Pubitemid 41389198)
106. W.L. Klein, W.B. Stine Jr., and D.B. Teplow Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease Neurobiol Aging 25 2004 569 580 (Pubitemid 38686476)
107. Y. Porat, S. Kolusheva, R. Jelinek, and E. Gazit The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies Biochemistry 42 2003 10971 10977 (Pubitemid 37174388)
108. C. Canale, S. Torrassa, P. Rispoli, A. Relini, R. Rolandi, and M. Bucciantini et al. Natively folded HypF-N and its early amyloid aggregates interact with phospholipid monolayers and destabilize supported phospholipid bilayers Biophys J 91 2006 4575 4588 (Pubitemid 44904242)
109. M.J. Volles, S.J. Lee, J.C. Rochet, M.D. Shtilerman, T.T. Ding, and J.C. Kessler et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease Biochemistry 40 2001 7812 7819 (Pubitemid 32622972)
110. G. Valincius, F. Heinrich, R. Budvytyte, D.J. Vanderah, D.J. McGillivray, and Y. Sokolov et al. Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity Biophys J 95 2008 4845 4861
111. J.D. Green, L. Kreplak, C. Goldsbury, X. Li Blatter, M. Stolz, and G.S. Cooper et al. Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide J Mol Biol 342 2004 877 887 (Pubitemid 39165656)
112. Y. Sokolov, J.A. Kozak, R. Kayed, A. Chanturiya, C. Glabe, and J.E. Hall Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure J Gen Physiol 128 2006 637 647 (Pubitemid 44833376)
113. J. Hannig, D. Zhang, D.J. Canaday, M.A. Beckett, R.D. Astumian, and R.R. Weichselbaum et al. Surfactant sealing of membranes permeabilized by ionizing radiation Radiat Res 154 2000 171 177 (Pubitemid 30612917)
114. M. Bucciantini, G. Calloni, F. Chiti, L. Formigli, D. Nosi, and C.M. Dobson et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity J Biol Chem 279 2004 31374 31382 (Pubitemid 39037804)
115. C. Amador-Ortiz, W.L. Lin, Z. Ahmed, D. Personett, P. Davies, and R. Duara et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease Ann Neurol 61 2007 435 445 (Pubitemid 46878771)
116. R.L. Hamilton Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry Brain Pathol 10 2000 378 384 (Pubitemid 30431290)
117. I. Ferrer, R. Blanco, M. Carmona, B. Puig, R. Ribera, and M.J. Rey et al. Prion protein expression in senile plaques in Alzheimer's disease Acta Neuropathol 101 2001 49 56 (Pubitemid 32124500)
118. J.Q. Trojanowski Emerging Alzheimer's disease therapies: focusing on the future Neurobiol Aging 23 2002 985 990 (Pubitemid 35447778)
119. A.C. Wilson, B.N. Dugger, D.W. Dickson, and D.S. Wang TDP-43 in aging and Alzheimer's disease - a review Int J Clin Exp Pathol 4 2011 147 155
120. J.M. Olichney, D. Galasko, D.P. Salmon, C.R. Hofstetter, L.A. Hansen, and R. Katzman et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease Neurology 51 1998 351 357 (Pubitemid 28406305)
121. G.G. Kovacs, I. Milenkovic, A. Wohrer, R. Hoftberger, E. Gelpi, and C. Haberler et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series Acta Neuropathol 126 2013 365 384
122. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
123. S.B. Prusiner Novel proteinaceous infectious particles cause scrapie Science 216 1982 136 144 (Pubitemid 12089840)
124. M. Neumann, D.M. Sampathu, L.K. Kwong, A.C. Truax, M.C. Micsenyi, and T.T. Chou et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis Science 314 2006 130 133 (Pubitemid 44547757)
125. C.A. Lasagna-Reeves, D.L. Castillo-Carranza, U. Sengupta, J. Sarmiento, J. Troncoso, and G.R. Jackson et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease FASEB J 26 2012 1946 1959
126. F. Goni, F. Prelli, Y. Ji, H. Scholtzova, J. Yang, and Y. Sun et al. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease PLoS One 5 2010 e13391
127. S. Rasool, R. Albay 3rd, H. Martinez-Coria, L. Breydo, J. Wu, and S. Milton et al. Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice Mol Neurodegener 7 2012 37
128. S. Rasool, H. Martinez-Coria, S. Milton, and C.G. Glabe Nonhuman amyloid oligomer epitope reduces Alzheimer's-like neuropathology in 3×Tg-AD Transgenic Mice Mol Neurobiol 2013
129. A. Monsonego, and H.L. Weiner Immunotherapeutic approaches to Alzheimer's disease Science 302 2003 834 838 (Pubitemid 37339618)
130. S. Oddo, V. Vasilevko, A. Caccamo, M. Kitazawa, D.H. Cribbs, and F.M. LaFerla Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles J Biol Chem 281 2006 39413 39423 (Pubitemid 46041901)
131. S. Rasool, H. Martinez-Coria, J.W. Wu, F. LaFerla, and C.G. Glabe Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Abeta deposition and tau pathology in 3×Tg-AD mice J Neurochem 126 2013 473 482
132. M. Guerrero, D. Castillo-Carranza, C. Lasagna-Reeves, K. Dineley, S. Krishnamurthy, and G. Jackson et al. Modulation of Aβ oligomers in the Tg2576 Alzheimer's disease mouse model by a novel generic anti-oligomer specific antibody Soc Neurosci 2012 2012 P852.18/E30
133. J.W. Lee, Y.K. Lee, J.O. Ban, T.Y. Ha, Y.P. Yun, and S.B. Han et al. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice J Nutr 139 2009 1987 1993
134. K. Rezai-Zadeh, G.W. Arendash, H. Hou, F. Fernandez, M. Jensen, and M. Runfeldt et al. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice Brain Res 1214 2008 177 187
135. C. Wu, H. Lei, Z. Wang, W. Zhang, and Y. Duan Phenol red interacts with the protofibril-like oligomers of an amyloidogenic hexapeptide NFGAIL through both hydrophobic and aromatic contacts Biophys J 91 2006 3664 3672 (Pubitemid 44788309)
136. F.F. Liu, X.Y. Dong, L. He, A.P. Middelberg, and Y. Sun Molecular insight into conformational transition of amyloid beta-peptide 42 inhibited by (-)-epigallocatechin-3-gallate probed by molecular simulations J Phys Chem B 115 2011 11879 11887
137. D.E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst, L. Masino, and R. Lurz et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat Struct Mol Biol 15 2008 558 566 (Pubitemid 351799141)
138. H. Hatcher, R. Planalp, J. Cho, F.M. Torti, and S.V. Torti Curcumin: from ancient medicine to current clinical trials Cell Mol Life Sci 65 2008 1631 1652
139. E. Herczenik, and M.F. Gebbink Molecular and cellular aspects of protein misfolding and disease FASEB J 22 2008 2115 2133 (Pubitemid 351948631)
140. D.Y. Choi, Y.J. Lee, J.T. Hong, and H.J. Lee Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease Brain Res Bull 87 2012 144 153
141. M.E. Waltner-Law, X.L. Wang, B.K. Law, R.K. Hall, M. Nawano, and D.K. Granner Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production J Biol Chem 277 2002 34933 34940
142. S. Wolfram, Y. Wang, and F. Thielecke Anti-obesity effects of green tea: from bedside to bench Mol Nutr Food Res 50 2006 176 187 (Pubitemid 43325659)
143. M. Oz, D.E. Lorke, M. Hasan, and G.A. Petroianu Cellular and molecular actions of Methylene blue in the nervous system Med Res Rev 31 2011 93 117
144. E.M. Sontag, G.P. Lotz, N. Agrawal, A. Tran, R. Aron, and G. Yang et al. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models J Neurosci 32 2012 11109 11119
145. S. Taniguchi, N. Suzuki, M. Masuda, S. Hisanaga, T. Iwatsubo, and M. Goedert et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins J Biol Chem 280 2005 7614 7623 (Pubitemid 40349654)
146. C.M. Wischik, P.C. Edwards, R.Y. Lai, M. Roth, and C.R. Harrington Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines PNAS 93 1996 11213 11218 (Pubitemid 26333144)
147. M. Yamashita, T. Nonaka, T. Arai, F. Kametani, V.L. Buchman, and N. Ninkina et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models FEBS Lett 583 2009 2419 2424
148. P. Cavaliere, J. Torrent, S. Prigent, V. Granata, K. Pauwels, and A. Pastore et al. Binding of methylene blue to a surface cleft inhibits the oligomerization and fibrillization of prion protein Biochim Biophys Acta 1832 2013 20 28
149. M. Necula, R. Kayed, S. Milton, and C.G. Glabe Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct J Biol Chem 282 2007 10311 10324 (Pubitemid 47093410)
150. E.E. Congdon, J.W. Wu, N. Myeku, Y.H. Figueroa, M. Herman, and P.S. Marinec et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo Autophagy 8 2012 609 622
151. C. Korth, B.C. May, F.E. Cohen, and S.B. Prusiner Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease PNAS 98 2001 9836 9841 (Pubitemid 32769390)
152. C. Peter, D. Hongwan, A. Kupfer, and B.H. Lauterburg Pharmacokinetics and organ distribution of intravenous and oral methylene blue Eur J Clin Pharmacol 56 2000 247 250 (Pubitemid 30456685)
153. C.M. Wischik, P. Bentham, D.J. Wischik, and K.M. Seng O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks Alzheimers Dement 4 2008 T167
154. D.X. Medina, A. Caccamo, and S. Oddo Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity Brain Pathol 21 2011 140 149
155. V. Paban, C. Manrique, M. Filali, S. Maunoir-Regimbal, F. Fauvelle, and B. Alescio-Lautier Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model Neuropharmacology 76PtA 2013 68 79
156. F. van Bebber, D. Paquet, A. Hruscha, B. Schmid, and C. Haass Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish Neurobiol Dis 39 2010 265 271
157. A. Vaccaro, S.A. Patten, S. Ciura, C. Maios, M. Therrien, and P. Drapeau et al. Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio PLoS One 7 2012 e42117
158. J.N. Audet, G. Soucy, and J.P. Julien Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models Neuroscience 209 2012 136 143
159. S.A. Mandel, T. Amit, L. Kalfon, L. Reznichenko, O. Weinreb, and M.B. Youdim Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG) J Alzheimers Dis 15 2008 211 222
160. D.E. Ehrnhoefer, M. Duennwald, P. Markovic, J.L. Wacker, S. Engemann, and M. Roark et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models Hum Mol Genet 15 2006 2743 2751 (Pubitemid 44400401)
161. J. Bieschke, J. Russ, R.P. Friedrich, D.E. Ehrnhoefer, H. Wobst, and K. Neugebauer et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity PNAS 107 2010 7710 7715
162. F. Meng, A. Abedini, A. Plesner, C.B. Verchere, and D.P. Raleigh The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity Biochemistry 49 2010 8127 8133
163. Y. Porat, A. Abramowitz, and E. Gazit Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism Chem Biol Drug Des 67 2006 27 37 (Pubitemid 43881385)
164. N. Ferreira, M.J. Saraiva, and M.R. Almeida Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: in vivo evidence from FAP mice models PLoS One 7 2012 e29933
165. K. Rezai-Zadeh, D. Shytle, N. Sun, T. Mori, H. Hou, and D. Jeanniton et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice J Neurosci 25 2005 8807 8814 (Pubitemid 41362059)
166. D. Mereles, and W. Hunstein Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci 12 2011 5592 5603
167. M. Daval, S. Bedrood, T. Gurlo, C.J. Huang, S. Costes, and P.C. Butler et al. The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity AmyloidV 17 2010 118 128
168. N. Pandey, J. Strider, W.C. Nolan, S.X. Yan, and J.E. Galvin Curcumin inhibits aggregation of alpha-synuclein Acta Neuropathol 115 2008 479 489
169. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro J Neurosci Res 75 2004 742 750 (Pubitemid 38296087)
170. F. Yang, G.P. Lim, A.N. Begum, O.J. Ubeda, M.R. Simmons, and S.S. Ambegaokar et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J Biol Chem 280 2005 5892 5901 (Pubitemid 40280072)
171. Y. Masuda, M. Fukuchi, T. Yatagawa, M. Tada, K. Takeda, and K. Irie et al. Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid beta-protein fibrils Bioorg Med Chem 19 2011 5967 5974
172. N. Ferreira, M.J. Saraiva, and M.R. Almeida Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy Amyloid 19 Suppl 1 2012 39 42
173. M. Garcia-Alloza, L.A. Borrelli, A. Rozkalne, B.T. Hyman, and B.J. Bacskai Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model J Neurochem 102 2007 1095 1104 (Pubitemid 47174225)
174. S.A. Frautschy, W. Hu, P. Kim, S.A. Miller, T. Chu, and M.E. Harris-White et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology Neurobiol Aging 22 2001 993 1005 (Pubitemid 34070638)
175. G.P. Lim, T. Chu, F. Yang, W. Beech, S.A. Frautschy, and G.M. Cole The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse J Neurosci 21 2001 8370 8377 (Pubitemid 33051435)
176. Q-L. Ma, F. Yang, E.R. Rosario, O.J. Ubeda, W. Beech, and D.J. Gant et al. β-Amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin J Neurosci 29 2009 9078 9089
177. L. Baum, C.W. Lam, S.K. Cheung, T. Kwok, V. Lui, and J. Tsoh et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease J Clin Psychopharmacol 28 2008 110 113
178. J.M. Ringman, S.A. Frautschy, E. Teng, A.N. Begum, J. Bardens, and M. Beigi et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study Alzheimers Res Ther 4 2012 43
179. J.M. Ringman, G. Cole, E. Teng, V. Badmaev, J. Bardens, and S. Frautschy et al. P4-344: oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study Alzheimers Dement 4 2008 T774
180. P.E. Potter Curcumin: a natural substance with potential efficacy in Alzheimer's disease J Exp Pharmacol 5 2013 23 31
181. N. Ferreira, MJo Saraiva, and MRr. Almeida Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation FEBS Letters 585 2011 2424 2430
182. N. Ferreira, S.A. Santos, M.R. Domingues, M.J. Saraiva, and M.R. Almeida Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition Biochim Biophys Acta 1832 2013 39 45
183. B. Ahmad, and L.J. Lapidus Curcumin prevents aggregation in alpha-synuclein by increasing reconfiguration rate J Biol Chem 287 2012 9193 9199
184. M.S. Wang, S. Boddapati, S. Emadi, and M.R. Sierks Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model BMC Neurosci 11 2010 57
185. P. Dikshit, A. Goswami, A. Mishra, N. Nukina, and N.R. Jana Curcumin enhances the polyglutamine-expanded truncated N-terminal huntingtin-induced cell death by promoting proteasomal malfunction Biochem Biophys Res Commun 342 2006 1323 1328
186. Y. Feng, X.P. Wang, S.G. Yang, Y.J. Wang, X. Zhang, and X.T. Du et al. Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation Neurotoxicology 30 2009 986 995
187. A.R. Ladiwala, J.C. Lin, S.S. Bale, A.M. Marcelino-Cruz, M. Bhattacharya, and J.S. Dordick et al. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers J Biol Chem 285 2010 24228 24237
188. R. Mishra, D. Sellin, D. Radovan, A. Gohlke, and R. Winter Inhibiting islet amyloid polypeptide fibril formation by the red wine compound resveratrol ChemBioChem 10 2009 445 449
189. D. Radovan, N. Opitz, and R. Winter Fluorescence microscopy studies on islet amyloid polypeptide fibrillation at heterogeneous and cellular membrane interfaces and its inhibition by resveratrol FEBS Lett 583 2009 1439 1445
190. F. Evers, C. Jeworrek, S. Tiemeyer, K. Weise, D. Sellin, and M. Paulus et al. Elucidating the mechanism of lipid membrane-induced IAPP fibrillogenesis and its inhibition by the red wine compound resveratrol: a synchrotron X-ray reflectivity study J Am Chem Soc 131 2009 9516 9521
191. A. Conte, S. Pellegrini, and D. Tagliazucchi Synergistic protection of PC12 cells from beta-amyloid toxicity by resveratrol and catechin Brain Res Bull 62 2003 29 38 (Pubitemid 37330112)
192. P. Marambaud, H. Zhao, and P. Davies Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides J Biol Chem 280 2005 37377 37382 (Pubitemid 41642343)
193. R.L. Frozza, A. Bernardi, J.B. Hoppe, A.B. Meneghetti, A. Matte, and A.M. Battastini et al. Neuroprotective effects of resveratrol against Abeta administration in rats are improved by lipid-core nanocapsules Mol Neurobiol 47 2013 1066 1080
194. S.S. Karuppagounder, J.T. Pinto, H. Xu, H.L. Chen, M.F. Beal, and G.E. Gibson Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease Neurochem Int 54 2009 111 118
195. J.A. Parker, M. Arango, S. Abderrahmane, E. Lambert, C. Tourette, and H. Catoire et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons Nat Genet 37 2005 349 350
196. J. Zhang, X. Feng, J. Wu, H. Xu, G. Li, and D. Zhu et al. Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by beta-amyloid through activation of SIRT1/Akt1 pathway Biofactors 2013
197. Y. Wu, X. Li, J.X. Zhu, W. Xie, W. Le, and Z. Fan et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease Neurosignals 19 2011 163 174
198. J. Wang, L. Ho, W. Zhao, K. Ono, C. Rosensweig, and L. Chen et al. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease J Neurosci 28 2008 6388 6392
199. J. Tome-Carneiro, M. Larrosa, A. Gonzalez-Sarrias, F.A. Tomas-Barberan, M.T. Garcia-Conesa, and J.C. Espin Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence Curr Pharm Des 19 2013 6064 6093
200. K.R. Patel, E. Scott, V.A. Brown, A.J. Gescher, W.P. Steward, and K. Brown Clinical trials of resveratrol Ann NY Acad Sci 1215 2011 161 169
201. S. Sinha, D.H.J. Lopes, Z. Du, E.S. Pang, A. Shanmugam, and A. Lomakin et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins J Am Chem Soc 133 2013 16958 16969
202. S. Prabhudesai, S. Sinha, A. Attar, A. Kotagiri, A.G. Fitzmaurice, and R. Lakshmanan et al. A novel "molecular tweezer" inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo Neurotherapeutics 9 2012 464 476
203. A. Attar, C. Ripoli, E. Riccardi, P. Maiti, D.D. Li Puma, and T. Liu et al. Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers Brain 135 2012 3735 3748
204. S. Rigacci, V. Guidotti, M. Bucciantini, D. Nichino, A. Relini, and A. Berti et al. Abeta(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon Curr Alzheimer Res 8 2011 841 852
205. S. Rigacci, V. Guidotti, M. Bucciantini, M. Parri, C. Nediani, and E. Cerbai et al. Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin J Nutr Biochem 21 2010 726 735
206. A. Daccache, C. Lion, N. Sibille, M. Gerard, C. Slomianny, and G. Lippens et al. Oleuropein and derivatives from olives as Tau aggregation inhibitors Neurochem Int 58 2011 700 707
207. P.A. Galanakis, F.N. Bazoti, J. Bergquist, K. Markides, G.A. Spyroulias, and A. Tsarbopoulos Study of the interaction between the amyloid beta peptide (1-40) and antioxidant compounds by nuclear magnetic resonance spectroscopy Biopolymers 96 2011 316 327
208. L. Diomede, S. Rigacci, M. Romeo, M. Stefani, and M. Salmona Oleuropein aglycone protects transgenic C. elegans strains expressing Abeta42 by reducing plaque load and motor deficit PLoS One 8 2013 e58893
209. M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou, and A.L. Fink The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils J Biol Chem 279 2004 26846 26857 (Pubitemid 38812518)
210. A.J. Gauci, M. Caruana, A. Giese, C. Scerri, and N. Vassallo Identification of polyphenolic compounds and black tea extract as potent inhibitors of lipid membrane destabilization by Abeta(4)(2) aggregates J Alzheimers Dis 27 2011 767 779
211. M. Caruana, J. Neuner, T. Högen, F. Schmidt, F. Kamp, and C. Scerri et al. Polyphenolic compounds are novel protective agents against lipid membrane damage by α-synuclein aggregates in vitro Biochim Biophys Acta 1818 2012 2502 2510
212. R.C. Choi, J.T. Zhu, A.W. Yung, P.S. Lee, S.L. Xu, and A.J. Guo et al. Synergistic action of flavonoids, baicalein, and daidzein in estrogenic and neuroprotective effects: a development of potential health products and therapeutic drugs against Alzheimer's disease Evid Based Complement Alternat Med 2013 2013 635694
213. F. Yin, J. Liu, X. Ji, Y. Wang, J. Zidichouski, and J. Zhang Baicalin prevents the production of hydrogen peroxide and oxidative stress induced by Aβ aggregation in SH-SY5Y cells Neurosci Lett 492 2011 76 79
214. J.-H. Lu, M.T. Ardah, S.S.K. Durairajan, L.-F. Liu, L.-X. Xie, and Fong W-FD et al. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation ChemBioChem 12 2011 615 624
215. J. Wagner, S. Ryazanov, A. Leonov, J. Levin, S. Shi, and F. Schmidt et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease Acta Neuropathol 125 2013 795 813
216. Y. Porat, Y. Mazor, S. Efrat, and E. Gazit Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions Biochemistry 43 2004 14454 14462 (Pubitemid 39491980)
217. M. Levy-Sakin, M. Shreberk, Y. Daniel, and E. Gazit Targeting insulin amyloid assembly by small aromatic molecules: toward rational design of aggregation inhibitors Islets 1 2009 210 215
218. F. Yin, J. Liu, X. Ji, Y. Wang, J. Zidichouski, and J. Zhang Silibinin: A novel inhibitor of Aβ aggregation Neurochem Int 58 2011 399 403
219. B. Cheng, H. Gong, X. Li, Y. Sun, X. Zhang, and H. Chen et al. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide Biochem Biophys Res Commun 419 2012 495 499
220. B. Cheng, H. Gong, X. Li, Y. Sun, H. Chen, and X. Zhang et al. Salvianolic acid B inhibits the amyloid formation of human islet amyloid polypeptideand protects pancreatic beta-cells against cytotoxicity Proteins: Struct Funct Bioinf 81 2013 613 621
221. M.K. Tang, and J.T. Zhang Salvianolic acid B inhibits fibril formation and neurotoxicity of amyloid beta-protein in vitro Acta Pharmacol Sin 22 2001 380 384